Sign in
TerminatedPhase 4

A Clinical Trial Comparing the OMNI Surgical System to Standard Medical Treatment in Patients With Primary Open Angle Glaucoma

Key facts

Who runs it
Sight Sciences, Inc.
Where
Maryville and Petaluma, United StatesSee the 2 sites
Trial code
Status
Terminated
Phase
Phase 4
People taking part
2 people enrolled
Started
21 Aug 2024
Ended
20 Jan 2025
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • OMNI Surgical System
  • Latanoprost plus adjunctive glaucoma medication
Record updated
29 January 2025
Why it stopped
Business decision by the Sponsor

Who can take part

Age
45 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Male or female subjects, 45 years or older
  • History of uncomplicated cataract surgery and posterior chamber intraocular lens (IOL) implantation without compromise to the lens capsule, zonular dehiscence/rupture or vitreous prolapse, 6 months or more prior to Baseline Visit (pseudophakic subjects), OR, phakic and no anticipated need for cataract surgery over the study duration
  • Under treatment with a topical prostaglandin F2 analog (e.g. latanoprost, travoprost, bimatoprost, tafluprost) either as monotherapy or in combination with one (1) adjunctive medication for a minimum of 6 weeks prior to the Screening visit
  • Intraocular pressure (IOP) at the Screening visit of >18 and not exceeding 36 mmHg
  • Diagnosed with primary open angle glaucoma (POAG)

Who cannot take part

  • Any of the following prior ocular procedures:; Laser trabeculoplasty ≤180 days prior to baseline; Durysta ≤12 months prior to baseline unless failure is documented and topical medication including a prostaglandin analog is in use as per Inclusion criterion # 3; Implanted with iStent (All types), Cypass, Xen, Express, glaucoma draining device/valve, or Hydrus Device; or; Prior canaloplasty, goniotomy, trabeculotomy, trabeculectomy, endoscopic cyclophotocoagulation (ECP), Cyclophotocoagulation or CPC (G probe); Retinal laser procedure ≤3 months prior to baseline
  • Concurrent IOP-lowering procedure other than the study procedure (OSS) (e.g. ECP, CPC,etc.)
  • Forms of glaucoma other than POAG including but not limited to: Pigmentary, pseudoexfoliative, acute angle closure, normal tension, pre-perimetric, traumatic, congenital, malignant, uveitic, neovascular or severe glaucoma as documented in subject's medical record
  • Women of childbearing potential if they are currently pregnant or intend to become pregnant during the study period; are breast-feeding; or are not in agreement to use adequate birth control methods to prevent pregnancy throughout the study

Where in United States

  • University Eye SpecialistsMaryville, United States
  • North Bay Eye AssociatesPetaluma, United States

About the trial

What the trial wants to find out

A Randomized Clinical Trial of Ab Interno Canaloplasty and Trabeculotomy with the OMNI® Surgical System Compared to Standard Medical Treatment as a Standalone Procedure in Patients with Primary Open Angle Glaucoma (EVOLVE)

The 2 groups in the trial

  • Surgical (OMNI Surgical System (OSS))Existing treatment, for comparison

    Canaloplasty followed by Trabeculotomy using the OMNI Surgical System.

    Treatment: OMNI Surgical System

  • Standard Medical Care (SMC)Existing treatment, for comparison

    Standard Medical Care with Latanoprost and one or two adjunctive glaucoma medications at the discretion of the Principal Investigator

    Treatment: Latanoprost plus adjunctive glaucoma medication

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
A Randomized Clinical Trial of ab Interno Canaloplasty and Trabeculotomy With the OMNI Surgical System Compared to Standard Medical Treatment as a Standalone Procedure in Patients With Primary Open Angle Glaucoma
Record updated
29 January 2025